Beryl Drugs Limited
Bombay Stock ExchangeTotal Valuation
Beryl Drugs Limited carries a market capitalization of 108.43M, placing it among publicly traded companies globally. Its enterprise value stands at 115.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 108.43M |
| Enterprise Value | 115.41M |
Valuation Ratios
Beryl Drugs Limited trades at a trailing price-to-earnings ratio of 818.54.
| PE Ratio | 818.54 |
| PS Ratio | 0.66 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Beryl Drugs Limited trades at an EV/EBITDA multiple of 25.57 and an EV/FCF ratio of 120.88. The EV/Sales ratio of 0.66 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.57 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.66 |
| EV / EBITDA | 25.57 |
| EV / EBIT | 25.57 |
| EV / FCF | 120.88 |
Financial Position
Beryl Drugs Limited maintains a current ratio of 3.50, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 88.29, indicating elevated leverage, while an interest coverage ratio of -2.83 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.50 |
| Quick Ratio | 0.23 |
| Debt / Equity | 88.29 |
| Debt / EBITDA | N/A |
| Interest Coverage | -2.83 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 4.18 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Beryl Drugs Limited has paid -1.90M in income taxes, reflecting an effective tax rate of 170.55.
| Income Tax | -1.90M |
| Effective Tax Rate | 170.55 |
Stock Price Statistics
Beryl Drugs Limited's stock has gained approximately 10.83463% over the past 52 weeks. The 50-day moving average sits at 21.43, while the 200-day moving average is 22.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | 10.83463% |
| 50-Day Moving Average | 21.43 |
| 200-Day Moving Average | 22.30 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Beryl Drugs Limited generated 174.63M in revenue and converted that into 141,000.00 in net income, yielding earnings per share of 0.03. EBITDA reached -9.65M, while operating income came in at -9.65M.
| Revenue | 174.63M |
| Gross Profit | 41.39M |
| Operating Income | -9.65M |
| Pretax Income | -1.80M |
| Net Income | 141,000.00 |
| EBITDA | -9.65M |
| EBIT | -9.65M |
| Earnings Per Share (EPS) | 0.03 |
Margins
Beryl Drugs Limited operates with a gross margin of 23.70, reflecting its pricing power and cost economics. The operating margin of -5.53 and net profit margin of 0.08 provide insight into operational efficiency.
| Gross Margin | 23.70 |
| Operating Margin | -5.53 |
| Pretax Margin | -1.03 |
| Profit Margin | 0.08 |
| EBITDA Margin | -5.53 |
Scores
Beryl Drugs Limited posts an Altman Z-Score of 4.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.07 |